Cytosorbents Co. (CTSO) COO Sells $64,386.00 in Stock

Cytosorbents Co. (NASDAQ:CTSO) COO Vincent Capponi sold 7,154 shares of the company’s stock in a transaction on Tuesday, May 15th. The shares were sold at an average price of $9.00, for a total transaction of $64,386.00. Following the completion of the sale, the chief operating officer now directly owns 321,551 shares of the company’s stock, valued at approximately $2,893,959. The sale was disclosed in a filing with the SEC, which is accessible through this link.

Vincent Capponi also recently made the following trade(s):

  • On Thursday, May 17th, Vincent Capponi sold 28,000 shares of Cytosorbents stock. The shares were sold at an average price of $10.00, for a total transaction of $280,000.00.

NASDAQ:CTSO traded up $0.50 during midday trading on Friday, reaching $10.55. 587,148 shares of the stock traded hands, compared to its average volume of 257,980. Cytosorbents Co. has a 12 month low of $3.30 and a 12 month high of $10.90. The company has a quick ratio of 5.99, a current ratio of 6.16 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $316.84 million, a P/E ratio of -32.97 and a beta of -0.08.

Cytosorbents (NASDAQ:CTSO) last posted its quarterly earnings results on Thursday, March 8th. The medical research company reported ($0.12) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.02). Cytosorbents had a negative net margin of 56.06% and a negative return on equity of 88.39%. The firm had revenue of $4.65 million for the quarter, compared to the consensus estimate of $4.56 million. analysts anticipate that Cytosorbents Co. will post -0.46 EPS for the current year.

A number of large investors have recently bought and sold shares of the stock. Millennium Management LLC raised its holdings in Cytosorbents by 134.4% during the 1st quarter. Millennium Management LLC now owns 384,330 shares of the medical research company’s stock valued at $2,710,000 after buying an additional 220,353 shares during the last quarter. B. Riley Financial Inc. bought a new stake in Cytosorbents during the 4th quarter valued at $992,000. Raymond James & Associates raised its holdings in Cytosorbents by 100.0% during the 4th quarter. Raymond James & Associates now owns 100,000 shares of the medical research company’s stock valued at $650,000 after buying an additional 50,000 shares during the last quarter. PEAK6 Investments L.P. raised its holdings in Cytosorbents by 13.7% during the 4th quarter. PEAK6 Investments L.P. now owns 99,744 shares of the medical research company’s stock valued at $648,000 after buying an additional 12,022 shares during the last quarter. Finally, BlueCrest Capital Management Ltd bought a new stake in Cytosorbents during the 4th quarter valued at $396,000. Institutional investors own 10.22% of the company’s stock.

CTSO has been the subject of a number of research reports. HC Wainwright set a $14.00 price objective on shares of Cytosorbents and gave the company a “buy” rating in a research note on Friday, March 9th. B. Riley reaffirmed a “buy” rating and issued a $11.25 price objective on shares of Cytosorbents in a research note on Thursday, January 25th. ValuEngine raised shares of Cytosorbents from a “hold” rating to a “buy” rating in a research note on Tuesday, April 3rd. Maxim Group set a $12.00 price objective on shares of Cytosorbents and gave the company a “buy” rating in a research note on Friday, March 9th. Finally, Cowen set a $9.00 price objective on shares of Cytosorbents and gave the company a “buy” rating in a research note on Thursday, March 8th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $11.25.

Cytosorbents Company Profile

Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors.

Insider Buying and Selling by Quarter for Cytosorbents (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply